KRAS and neoplasm: Most recently, the next-generation inhibitor D3S-001 demonstrated a confirmed ORR of 73.5% in KRAS G12C inhibitor-naïve patients across tumor types, including 67% in NSCLC, 89% in CRC, and 75% in PDAC (NCT05410145), further reinforcing the tissue-transcending potential of KRAS G12C-directed therapies [97].